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Abstract: All the reports to date on the anti-inflammatory activity of chitooligosaccharides 
(COS) are mostly based on in vitro methods. In this work, the anti-inflammatory activity of 
two COS mixtures is characterized in vivo (using balb/c mice), following the carrageenan-
induced paw edema method. This is a widely accepted animal model of acute inflammation 
to  evaluate  the  anti-inflammatory  effect  of  drugs.  Our  data  suggest  that  COS  possess  
anti-inflammatory activity, which is dependent on dose and, at higher doses, also on the 
molecular weight. A single dose of 500 mg/kg b.w. weight may be suitable to treat acute 
inflammation cases; however, further studies are needed to ascertain the effect upon longer 
inflammation periods as well as studies upon the bioavailability of these compounds. 
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1. Introduction 
Chitooligosaccharides (COS) are partially hydrolyzed products of chitosan, a biopolymer composed 
of  β-(1-4)-linked  N-acetyl-D-glucosamine  and  deacetylated  glucosamine  units  [1].  Several  authors 
have reported the potential of COS as a therapeutic agent against inflammation. These studies were 
mainly based on in vitro tests [2–4]. It has been suggested that this anti-inflammatory action of COS 
occurs via down-regulation of transcriptional and translational expression levels of TNF-α, IL-6, iNOS 
and COX-2 [4–6]; furthermore, it depends on the molecular weight of COS [6]. This preliminary 
study, therefore, intends to investigate the anti-inflammatory activities of COS mixtures with different 
molecular weights, by studying its effects in vivo upon inflammation induced by carrageenan. 
2. Results and Discussion 
Both COS mixtures administered orally at doses between 50–1,000 mg/kg b.w., didn’t generate any 
significant change in the autonomic or behavioural responses during the observation period. Therefore, 
the oral LD50 value in mice, for both COS, was found to be above 1,000 mg/kg b.w. 
Edema  induced  by  phlogistic  agents  is  a  widely  accepted  model  for  the  evaluation  of  
anti-inflammatory effect of drugs [7]. Carrageenan-induced paw edema is a classical model of acute 
inflammation (used mainly for testing the nonsteroidal anti-inflammatory drugs, as INN) involving 
various types of chemical mediators of inflammation such as histamine, serotonin, bradykinin and 
prostaglandins,  in  which  the  involvement  of  the  cyclooxygenase  products  of  arachidonic  acid 
metabolism and the production of reactive oxygen species are well established
 [8]. Development of 
edema induced by carrageenan is commonly correlated with the early exudative stage of inflammation, 
one  of  the  important  processes  of  inflammatory  pathology  [9].In  the  beginning  of  carrageenan 
injection,  there  is  sudden  elevation  of  paw  volume  as  consequence  of  histamine  liberation  from 
mastocyte cells [10]. After 1 h the inflammation increases gradually and is elevated during the later  
3–6 h. This second phase is mediated by prostaglandins, cyclooxygenase products. Continuity between 
the two phases is provided by kinins [11,12]. 
To demonstrate the validity of the carrageenan-induced paw edema test, mice were administered 
INN orally as a positive control at a dosage of 10 mg/kg b.w. 1 h before carrageenan injection. As 
expected, INN significantly (p < 0.05) decreased paw edema at 2, 3 and 6 h after carrageenan injection 
compared to saline, with inhibition levels of 67.92%, 71.61% and 78.79%, respectively (Figure 1). 
These results demonstrate that INN, a cyclooxygenase inhibitor, exerts an anti-edematous effect during 
the  second  phase  of  paw  edema  due  to  the  reduction  of  prostaglandins,  which  are  second  phase 
inflammatory mediators. Simultaneously, mice were administered various doses of COS3 and COS5 
(10–500  mg/kg  b.w.)  orally  1  h  before  carrageenan  administration.  All  tested  concentrations 
significantly  (p  <  0.05)  decreased  the  paw  volume  at  3  and  6  h  after  carrageenan  administration 
compared to vehicle control (Figure 1). Both COS showed higher action at 500 mg/kg, decreasing the 
paw volume significantly compared to the other tested concentrations. Also, at this concentration the 
molecular weight proved to play a major role reducing paw volume, since COS3 showed significant  
(p  <  0.05)  stronger  effect–73.42%  and  78.13%,  than  COS5–63.20%  and  71.88%  at  3  and  6  h, 
respectively. Mar. Drugs 2010, 8               
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Figure  1.  Effect  of  various  doses  of  both  COS,  administered  orally  60  min  prior  to 
injection  of  carrageenan,  on  mice  paw  edema  volume  (mL),  after  3  and  6  h.  
(Average ±  S.E.M.).  
 
Legend:  (a)  statistically  different  from  all  other  compounds  tested  (p  <  0.05),  except  b;  
(b) statistically different from all other compounds tested (p < 0.05), except a; (c) statistically 
different (p < 0.05) from COS3–500 mg and INN at 3 and 6 h; (d) statistically different from 
COS3–500  mg  and  INN  at  3  and  6  h;  (e)  statistically  different  (p  <  0.05)  from  other  COS3 
concentrations; (e*) statistically different from COS5–500 mg at 6 h (p < 0.05); (f) statistically 
different  from  other  COS5  concentrations;  (g)  statistically  different  from  COS3  and  COS5 
concentrations, except 500 mg values (p < 0.05).  
Overall every dose of COS3 and COS5 tested in this study showed significant reduction of paw 
edema  at  2  h  after  carrageenan  injection,  suggesting  that  COS  produces  an  anti-edematous  effect 
during the second phase, similarly to INN. Therefore, our results suggest that the mechanism of the 
anti-inflammatory  effect  of  COS  may  involve  the  inhibition  of  the  cyclooxygenase  pathway;  as 
reported  elsewhere  [6],  COS  may  exert  their  anti-inflammatory  effect  via  down-regulation  of 
transcriptional and translational expression levels of COX-2. At this stage, an endpoint was established 
in order to prevent animals from suffering a severe discomfort resulting from leg ulceration. However, 
the experiment was extended with the INN group (which showed to be more effective than Dexa as a 
positive control), and with the most promising COS concentration–500 mg/kg (Figure 2). 
COS3 continued to exert anti-inflammatory activity, comparable to INN until the 24 h, while COS5 
started losing activity around the 15 h–which may be related to a lower level of COS5 in the blood 
circulation, due to its higher MW and concomitant lower absorption rate at intestinal level [1]; by 48 h, 
both COS mixtures presented a similar effect (between 43–47%), lower than INN (81.81%) but still 
significantly  different  from  the  negative  control  (p  <  0.05).  After  euthanasia,  no  changes  were 
observed in COS3 and COS5 administered mice. Kidneys, liver, stomach, heart and intestines were 
analyzed for visible alterations and weighted, presenting no differences compared to control mice; 
however,  the  group  administered  with  INN,  had  considerably  inflated  and  heavier  stomachs  and 
intestines–which can be associated to the peptic ulcer inducing effect of INN [13]. 
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Figure  2.  Effect of 500 mg/kg b.w. of both COS, administered orally 60 min prior to 
injection  of  carrageenan,  on  mice  paw  edema  volume  (mL),  along  the  time  
(Average ±  S.E.M.). 
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3. Experimental Section  
3.1. Materials 
Chitooligosaccharide  mixtures  characterized  by  two  distinct  average  molecular  weights—1.2 
(COS3) and 5.3 kDa (COS5)—and possessing a degree of deacetylation in the 80–85% range, were 
purchased from Nicechem (Shanghai, China). Both compounds were derived from crab shells. All 
chemicals used in this work were purchased from Sigma-Brazil. 
3.2. Animals 
Balb/c male mice (6 weeks), weighing between 27 and 32 g, were used in the experiments. The 
animals were purchased from Centro Multidisciplinar para Investigaç ã o Bioló gica na Área da Ciê ncia 
em Animais de Laborató rio–CEMIB at the University of Campinas (UNICAMP), and were kept in 
polyethylene boxes (n = 6), in a controlled environment—constant temperature (24 ±  2 ° C) with a 12 h 
light-dark cycle and relative humidity of 40–70%. They were kept without food for 24 h before the 
experiment and water was ad libitum. Groups of six mice were used and the studies were carried out in 
accordance  with  current  guidelines  for  the  veterinary  care  of  laboratory  animals  [14],  and  were 
performed under the consent and surveillance of Unicamp’s Institute of Biology Ethics Committee for 
Animal Research (1076-1).  
3.3. Preliminary screening and acute toxicity assessment 
Mice were divided into seven groups, each containing six animals. COS mixtures were administered 
orally, in varying doses (50, 250 and 1,000 mg/kg b.w.) to these animals, using saline solution as a 
vehicle.  A  group  of  animals  treated  with  the  vehicle  served  as  control.  They  were  continuously 
observed  for  4  h  to  detect  changes  in  their  autonomic  or  behavioural  responses  viz.  alertness, 
spontaneous  activity,  irritability,  pinna  reflex,  corneal  reflex,  urination,  salivation  and  Mar. Drugs 2010, 8               
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piloerection [15]. Any mortality during this period of experimentation and along the following 14 days 
was also recorded. Based on the results of this preliminary toxicity test, doses of 10, 30, 100 and  
500 mg/kg b.w. were chosen to study the anti-inflammatory activity of COS mixtures. 
3.4. Acute inflammation assessment 
Anti-inflammatory activity was studied by carrageenan-induced paw edema method [7]. Mice were 
divided into eleven groups, each containing six animals. COS mixtures were administered orally in 
different doses (10, 30, 100 and 500 mg/kg b.w.), 60 min prior to carrageenan injection. Two positive 
control  groups  [16]  were  used:  one  with  10  mg/kg  b.w.  of  indomethacin  (INN–a  well-known  
non-steroidal anti-inflammatory drug), and the other with 1 mg/kg b.w. of dexamethasone (Dexa–a 
potent synthetic member of the glucocorticoid class of steroid hormones). A group of animals treated 
with  the  vehicle  served  as  negative  control.  Edema  was  induced  by  injecting  0.02  ml  of  2.5% 
carrageenan in sterile saline into the plantar surface of the right hind paw. The difference of volumes 
between the basal and sequential measurements in the right hind paw was calculated as the edema 
formation. The paw volume was measured in an Ugo Basile plethysmometer (Comerio VA, Italy), at 
0.5, 1, 2, 3, 4, 6, 8, 24 and 48 h.  
3.5. Statistical analysis 
The  results  are  expressed  as  mean  ±  SEM  (n  =  6).  Statistical  significance  was  determined  by 
analysis  of  variance  and  subsequent  Duncan’s  multiple  range  test  (p  <  0.05).  The  analysis  was 
performed  using  Statistical  Package  for  Social  Sciences  –  SPSS  statistical  software  (Chicago,  
IL, USA). 
4. Conclusions  
In conclusion, our data suggests that COS are able to induce anti-inflammatory effect mediated by 
cyclooxygenase inhibition and consequent reduction of prostaglandins. In addition, the efficacy of 
high-dose  COS3  (500  mg/kg  b.w.)  was  comparable  to  that  of  indomethacin,  but  during  a  shorter 
period. A single dose of 500 mg/kg b.w. may indeed be suitable to treat acute inflammation cases; 
however, further studies are needed to ascertain the effect upon longer inflammation periods as well as 
studies upon the bioavailability of these compounds. 
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